Stelloo E - Search Results

1

POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.

van Gool IC, Eggink FA, Freeman-Mills L, Stelloo E, Marchi E, de Bruyn M, Palles C, Nout RA, de Kroon CD, Osse EM, Klenerman P, Creutzberg CL, Tomlinson IP, Smit VT, Nijman HW, Bosse T, Church DN. van Gool IC, et al. Among authors: stelloo e. Clin Cancer Res. 2015 Jul 15;21(14):3347-3355. doi: 10.1158/1078-0432.CCR-15-0057. Epub 2015 Apr 15. Clin Cancer Res. 2015. PMID: 25878334 Free PMC article.

2

Targeted locus amplification to develop robust patient-specific assays for liquid biopsies in pediatric solid tumors.

van Zogchel LMJ, Lak NSM, Gelineau NU, Sergeeva I, Stelloo E, Swennenhuis J, Feitsma H, van Min M, Splinter E, Bleijs M, Groot Koerkamp M, Breunis W, Meister MT, Kholossy WH, Holstege FCP, Molenaar JJ, de Leng WWJ, Stutterheim J, van der Schoot CE, Tytgat GAM. van Zogchel LMJ, et al. Among authors: stelloo e. Front Oncol. 2023 Apr 20;13:1124737. doi: 10.3389/fonc.2023.1124737. eCollection 2023. Front Oncol. 2023. PMID: 37152023 Free PMC article.

3

High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.

Stelloo E, Nout RA, Naves LC, Ter Haar NT, Creutzberg CL, Smit VT, Bosse T. Stelloo E, et al. Gynecol Oncol. 2014 May;133(2):197-204. doi: 10.1016/j.ygyno.2014.02.012. Epub 2014 Feb 18. Gynecol Oncol. 2014. PMID: 24556061

4

Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers.

Spaans VM, Trietsch MD, Crobach S, Stelloo E, Kremer D, Osse EM, Haar NT, van Eijk R, Muller S, van Wezel T, Trimbos JB, Bosse T, Smit VT, Fleuren GJ. Spaans VM, et al. Among authors: stelloo e. PLoS One. 2014 Mar 26;9(3):e93451. doi: 10.1371/journal.pone.0093451. eCollection 2014. PLoS One. 2014. PMID: 24671188 Free PMC article.

5

L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results.

Bosse T, Nout RA, Stelloo E, Dreef E, Nijman HW, Jürgenliemk-Schulz IM, Jobsen JJ, Creutzberg CL, Smit VT. Bosse T, et al. Among authors: stelloo e. Eur J Cancer. 2014 Oct;50(15):2602-10. doi: 10.1016/j.ejca.2014.07.014. Epub 2014 Aug 7. Eur J Cancer. 2014. PMID: 25126672

6

Prognostic significance of POLE proofreading mutations in endometrial cancer.

Church DN, Stelloo E, Nout RA, Valtcheva N, Depreeuw J, ter Haar N, Noske A, Amant F, Tomlinson IP, Wild PJ, Lambrechts D, Jürgenliemk-Schulz IM, Jobsen JJ, Smit VT, Creutzberg CL, Bosse T. Church DN, et al. Among authors: stelloo e. J Natl Cancer Inst. 2014 Dec 12;107(1):402. doi: 10.1093/jnci/dju402. Print 2015 Jan. J Natl Cancer Inst. 2014. PMID: 25505230 Free PMC article.

7

Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.

Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, Leary A, Edmondson RJ, Powell ME, Crosbie EJ, Kitchener HC, Mileshkin L, Pollock PM, Smit VT, Creutzberg CL. Stelloo E, et al. Mod Pathol. 2015 Jun;28(6):836-44. doi: 10.1038/modpathol.2015.43. Epub 2015 Feb 27. Mod Pathol. 2015. PMID: 25720322 Free article.

8

Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.

Van Gool IC, Stelloo E, Nout RA, Nijman HW, Edmondson RJ, Church DN, MacKay HJ, Leary A, Powell ME, Mileshkin L, Creutzberg CL, Smit VT, Bosse T. Van Gool IC, et al. Among authors: stelloo e. Mod Pathol. 2016 Feb;29(2):174-81. doi: 10.1038/modpathol.2015.147. Epub 2016 Jan 8. Mod Pathol. 2016. PMID: 26743472 Free article.

9

Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.

Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Nijman HW, Putter H, Bosse T, Creutzberg CL, Smit VT. Stelloo E, et al. Clin Cancer Res. 2016 Aug 15;22(16):4215-24. doi: 10.1158/1078-0432.CCR-15-2878. Epub 2016 Mar 22. Clin Cancer Res. 2016. PMID: 27006490

10

Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer.

Stelloo E, Versluis MA, Nijman HW, de Bruyn M, Plat A, Osse EM, van Dijk RH, Nout RA, Creutzberg CL, de Bock GH, Smit VT, Bosse T, Hollema H. Stelloo E, et al. Oncotarget. 2016 Jun 28;7(26):39885-39893. doi: 10.18632/oncotarget.9414. Oncotarget. 2016. PMID: 27213585 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

37 results

Search Page

Filters